中文May 30, 2025
On May 29, BioGeometry and Nanning Harworld Biology held a strategic cooperation signing ceremony for “AI-Driven Synthetic Biology to Accelerate Cell Factory Development.” The partnership will focus on generative AI-powered enzyme design, enzyme mining, strain engineering, metabolic pathway optimization, and cell factory design, fostering deep integration of “AI + Synthetic Biology” in industrial applications.
By leveraging machine learning to analyze vast genomic and metabolomic datasets, BioGeometry’s GeoFlow V2—the first unified atomic protein model—can predict optimal gene-editing sites and reconstruct metabolic pathways. This breakthrough slashes the traditional “trial-and-error” strain development cycle from months or even years down to weeks, dramatically improving cell factory R&D efficiency and product performance.
As one of Guangxi’s largest private synthetic biology manufacturers, Harworld Biology specializes in green biomanufacturing, with products spanning bio-stimulants, microbial fertilizers, and novel functional ingredients for agriculture, food, and cosmetics. The company operates R&D centers in Nanning and Shenzhen (totaling 12,000+ sqm), backed by a top-tier scientific team and advanced facilities. It is recognized as a National High-Tech Enterprise and a Guangxi “Specialized & Innovative” SME representative.
Yu Yifa, Deputy General Manager of Harworld Biology, stated:
“Harworld Biology has always prioritized R&D innovation as our core driver. Partnering with BioGeometry allows us to leap forward in AI-powered synthetic biology, achieving systemic upgrades from foundational design to industrial applications.”
Dr. Jian Tang, Founder and CEO of BioGeometry, added:
“GeoFlow V2 represents a major leap in generative AI for biomanufacturing, propelling protein design into an intelligent, scalable future. We’re thrilled to collaborate with Harworld Biology, infusing AI capabilities into traditional fermentation processes to build smarter, more sustainable cell factories.”
As pioneers of China’s “AI+” and “Biomanufacturing” national strategies, the two companies will first address Harworld’s strain development needs, establishing a closed-loop R&D pipeline covering target prediction, protein design, functional validation and metabolic optimization.
Future efforts will expand into metabolic engineering and green material alternatives, injecting innovation into global sustainability while elevating China’s biomanufacturing leadership in the global value chain.